Page last updated: 2024-11-02

pentoxifylline and Cognitive Decline

pentoxifylline has been researched along with Cognitive Decline in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Due to the inflammatory factors in the pathophysiology of schizophrenia, Pentoxifylline, as anti-inflammatory medication, seems to improve the symptoms of schizophrenia."9.69Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial. ( Farid Hosseini, F; Fayyazi-Bordbar, M; Jamali, J; Mohammadpour, A; Sinichi, F; Sinichi, M, 2023)
"Due to the inflammatory factors in the pathophysiology of schizophrenia, Pentoxifylline, as anti-inflammatory medication, seems to improve the symptoms of schizophrenia."5.69Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial. ( Farid Hosseini, F; Fayyazi-Bordbar, M; Jamali, J; Mohammadpour, A; Sinichi, F; Sinichi, M, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Sinichi, F1
Farid Hosseini, F1
Fayyazi-Bordbar, M1
Sinichi, M1
Jamali, J1
Mohammadpour, A1

Trials

1 trial available for pentoxifylline and Cognitive Decline

ArticleYear
Pentoxifylline as adjunctive therapy in cognitive deficits and symptoms of schizophrenia: A randomized double-blind placebo-controlled clinical trial.
    Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:10

    Topics: Antipsychotic Agents; Cognition; Cognitive Dysfunction; Double-Blind Method; Drug Therapy, Combinati

2023